Antibody-drug conjugates (ADC) are an attractive approach for the treatment of acute
myeloid leukemia and non-Hodgkin lymphomas, which in most cases, are inherently …

The antibody-drug conjugate (ADC) concept is to use an antibody to deliver a cytotoxic drug
selectively to a target such as a tumor-associated antigen. Such conjugates represent a …

Purpose: SGN-35 is an antibody-drug conjugate (ADC) containing the potent antimitotic
drug, monomethylauristatin E (MMAE), linked to the anti-CD30 monoclonal antibody, cAC10 …

Abstract CD133/prominin-1 is a pentaspan transmembrane glycoprotein overexpressed in
various solid tumours including colorectal and glioblastomas. CD133 was found here to be …

The 9th web-based European Conference on Infections in Leukemia (ECIL-9), held
September 16-17, 2021, reviewed the risk of infections and febrile neutropenia associated …

While chemotherapy is successful at inducing remission of acute myeloid leukaemia (AML),
the disease has a high probability of relapse. Strategies to prevent relapse involve …

During the past decade, a growing body of evidence has implied that cancer stem cells
(CSCs) play an important role in the development of gastric cancer (GC). The notion that …

Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized
anti-CD33 antibody (hP67. 6) linked to N-acetyl-calicheamicin 1, 2-dimethyl hydrazine …

Background: Gemtuzumab ozogamicin consists of a semisynthetic derivative of
calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal …

Abstract Purpose CMC-544 (inotuzumab ozogamicin) is a CD22-specific immunoconjugate
of calicheamicin currently being evaluated in patients with non-Hodgkin's B-cell lymphoma …